Session Description
Lipoprotein(a) is an independent risk factor for cardiovascular disease and management strategies for this condition have been and will continue to change over the next few years. Specifically, an MTP session/chapter would cover details about measurement of Lp(a) (ie mg/dL vs nmol/L), current guideline recommendations regarding checking Lp(a) (ie universal screening now recommended by NLA), current therapeutic approach to high Lp(a) (ie use of ASA, PCSK9i, and resetting LDL-C goals), and future therapies on the horizon (ie four phase 3 trials for unique Lp(a) lowering drugs will be active by the end of 2024). I, David Saxon MD, would be happy to give this MTP session if selected. I am the Director of the Cardiometabolic and Advanced Lipid Clinic at the University of Colorado. We see many patients with high Lp(a) and offer intensive lipid lowering therapy including lipid apheresis and PCSK9i whe appropriate. We are also a site for 3 of the active Lp(a) drug lowering trials.